CA3017743A1 - Method of preventing graft versus host disease - Google Patents

Method of preventing graft versus host disease Download PDF

Info

Publication number
CA3017743A1
CA3017743A1 CA3017743A CA3017743A CA3017743A1 CA 3017743 A1 CA3017743 A1 CA 3017743A1 CA 3017743 A CA3017743 A CA 3017743A CA 3017743 A CA3017743 A CA 3017743A CA 3017743 A1 CA3017743 A1 CA 3017743A1
Authority
CA
Canada
Prior art keywords
humanized antibody
seq
gvhd
antibody
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3017743A
Other languages
English (en)
French (fr)
Inventor
Jessica A. SACHS
John E. Ford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA3017743A1 publication Critical patent/CA3017743A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3017743A 2016-03-14 2017-03-13 Method of preventing graft versus host disease Pending CA3017743A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US62/307,896 2016-03-14
PCT/US2017/022065 WO2017160699A2 (en) 2016-03-14 2017-03-13 Method of preventing graft versus host disease

Publications (1)

Publication Number Publication Date
CA3017743A1 true CA3017743A1 (en) 2017-09-21

Family

ID=58448610

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3017743A Pending CA3017743A1 (en) 2016-03-14 2017-03-13 Method of preventing graft versus host disease

Country Status (13)

Country Link
US (1) US20200002422A1 (enExample)
EP (1) EP3430052A2 (enExample)
JP (2) JP2019508448A (enExample)
KR (1) KR102710759B1 (enExample)
CN (2) CN116327920A (enExample)
AU (1) AU2017234009B2 (enExample)
BR (1) BR112018068628A2 (enExample)
CA (1) CA3017743A1 (enExample)
EA (1) EA201892071A1 (enExample)
IL (1) IL261750B2 (enExample)
MA (1) MA44408A (enExample)
MX (2) MX2018011169A (enExample)
WO (1) WO2017160699A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117298268A (zh) * 2016-03-14 2023-12-29 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
MA45245A (fr) 2016-06-12 2019-04-17 Millennium Pharm Inc Méthode de traitement de maladie intestinale inflammatoire
EP3749334B1 (en) 2018-02-08 2024-12-11 The Board of Trustees of the Leland Stanford Junior University Allogenic hematopoietic stem cell transplantation
EP4142755A4 (en) * 2020-04-27 2024-06-12 Children's Hospital Medical Center PRECISION DOSING SCHEME
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
PT808367E (pt) 1995-02-10 2007-10-22 Millennium Pharm Inc Adressinas vasculares da mucosa e suas utilizações
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
NZ566263A (en) 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
ATE363470T1 (de) 2002-11-18 2007-06-15 Chemocentryx Inc Arylsulfonamide
CN1956738B (zh) 2004-01-09 2013-05-29 辉瑞大药厂 MAdCAM抗体
SI1784426T1 (sl) 2004-09-03 2012-03-30 Genentech Inc Humanizirani antagonisti proti beta in njihove uporabe
CA2654446C (en) * 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
AU2006316629A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
HRP20150400T1 (hr) * 2008-11-07 2015-05-08 Amgen Research (Munich) Gmbh Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije
KR101391472B1 (ko) * 2009-03-20 2014-05-07 암젠 인크 알파-4-베타-7 이종이량체 특이적 길항제 항체
DK2637672T3 (en) * 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR101875155B1 (ko) * 2011-05-02 2018-07-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
NZ629204A (en) * 2012-02-16 2016-09-30 Santarus Inc Anti-vla1 (cd49a) antibody pharmaceutical compositions
SG10201704992SA (en) * 2012-06-21 2017-07-28 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
EP3182974A1 (en) * 2014-08-21 2017-06-28 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CN117298268A (zh) * 2016-03-14 2023-12-29 千禧制药公司 治疗或预防移植物抗宿主疾病的方法

Also Published As

Publication number Publication date
IL261750B2 (en) 2024-07-01
IL261750A (en) 2018-10-31
AU2017234009B2 (en) 2024-06-06
BR112018068628A2 (pt) 2019-07-30
CN116327920A (zh) 2023-06-27
WO2017160699A2 (en) 2017-09-21
MX2025001934A (es) 2025-04-02
WO2017160699A3 (en) 2017-11-23
US20200002422A1 (en) 2020-01-02
MA44408A (fr) 2019-01-23
IL261750B1 (en) 2024-03-01
JP2019508448A (ja) 2019-03-28
EA201892071A1 (ru) 2019-03-29
CN109071660A (zh) 2018-12-21
KR102710759B1 (ko) 2024-09-25
JP2022163078A (ja) 2022-10-25
MX2018011169A (es) 2018-12-06
KR20180120706A (ko) 2018-11-06
EP3430052A2 (en) 2019-01-23
AU2017234009A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
US12246064B2 (en) Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
JP5926702B2 (ja) Ｃｄ２００に対する抗体および免疫応答への使用
AU2017234009B2 (en) Method of preventing graft versus host disease
JP2023016923A (ja) 調節性ｔ細胞及びその使用
AU2024203289A1 (en) Methods of treating or preventing graft versus host disease
US20190194333A1 (en) Klrg1 depletion therapy
US20250122289A1 (en) Methods of treating or preventing graft versus host disease
EA041816B1 (ru) Способ профилактики болезни "трансплантат против хозяина"

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220310

EEER Examination request

Effective date: 20220310

EEER Examination request

Effective date: 20220310

EEER Examination request

Effective date: 20220310

EEER Examination request

Effective date: 20220310

EEER Examination request

Effective date: 20220310